Search Results - "Osborne, Stuart"
-
1
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
Published in The lancet oncology (01-10-2013)“…Summary Background Elderly patients are often under-represented in clinical trials of metastatic colorectal cancer. We aimed to assess the efficacy and safety…”
Get full text
Journal Article -
2
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Published in The lancet oncology (01-09-2013)“…Summary Background Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous…”
Get full text
Journal Article -
3
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
Published in Haematologica (Roma) (01-04-2018)“…MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic…”
Get full text
Journal Article -
4
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Published in Haematologica (Roma) (01-11-2017)“…Intravenous rituximab plus chemotherapy is standard treatment for diffuse large B-cell lymphoma. A subcutaneous formulation of rituximab is expected to…”
Get full text
Journal Article -
5
HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study
Published in Applied immunohistochemistry & molecular morphology (01-04-2018)“…Human epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in gastric/gastroesophageal junction cancer; however, the number…”
Get full text
Journal Article -
6
The use of a pre-operative scoring system for the prediction of phacoemulsification case difficulty and the selection of appropriate cases to be performed by trainees
Published in BMC ophthalmology (27-12-2006)“…To establish whether a previously validated scoring system (Habib) for the prediction of risk or likelihood of posterior capsule rupture during…”
Get full text
Journal Article -
7
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Published in Journal of neuro-oncology (01-11-2018)“…Purpose Glioblastoma is the most common primary malignant brain tumor. No standard treatment exists for recurrent disease. Glioblastoma is associated with an…”
Get full text
Journal Article -
8
Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC)
Published in Journal of clinical oncology (01-06-2023)“…9047 Background: NTRK fusions, encoding for constitutively active oncogenic tropomyosin receptor kinase proteins, are present in many solid tumors, including…”
Get full text
Journal Article -
9
Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple Oral administration
Published in Clinical pharmacokinetics (01-01-2003)“…To investigate the pharmacokinetics and tolerability of the new nonsteroid anti-inflammatory pimecrolimus (SDZ ASM 981, Elidel) after oral administration. A…”
Get full text
Journal Article -
10
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
Published in Lung cancer (Amsterdam, Netherlands) (01-02-2024)“…NTRK fusions result in constitutively active oncogenic TRK proteins responsible for ∼ 0.2 % of non-small cell lung cancer (NSCLC) cases. Approximately 40 % of…”
Get full text
Journal Article -
11
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
Published in British journal of cancer (11-12-2018)“…Background Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this…”
Get full text
Journal Article -
12
Abstract PS11-28: Efficacy and safety of entrectinib in NTRK fusion-positive ( NTRK -fp) breast cancer
Published in Cancer research (Chicago, Ill.) (15-02-2021)“…Abstract Neurotrophic tyrosine receptor kinase genes (NTRK1/2/3) act as oncogenic drivers across a range of tumors. NTRK fusions occur at low frequency (<5%)…”
Get full text
Journal Article -
13
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
Published in Breast (Edinburgh) (01-08-2017)“…Abstract Aim To assess the safety and tolerability of switching between subcutaneous (SC) and intravenous (IV) trastuzumab in the PrefHer study (NCT01401166)…”
Get full text
Journal Article -
14
Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC)
Published in Journal of clinical oncology (01-02-2018)“…Abstract only 726 Background: Primary tumor location is an important prognostic factor in mCRC. Efficacy differences with EGFR antibodies by tumor location…”
Get full text
Journal Article -
15
Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study
Published in Blood (08-12-2017)“…Introduction: Rituximab (R) plus chemotherapy (chemo) is standard of care for patients (pts) with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma…”
Get full text
Journal Article -
16
Prefmab: Final Analysis of Patient Preference for Subcutaneous Versus Intravenous Rituximab in Previously Untreated CD20+ Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Published in Blood (03-12-2015)“…Background Rituximab in combination with chemotherapy is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma…”
Get full text
Journal Article -
17
A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin's Lymphoma: Interim Safety Data From The Mabcute Study
Published in Blood (15-11-2013)“…Rituximab is part of the standard induction and maintenance therapy for most patients with first-line or relapsing indolent non-Hodgkin's lymphoma (iNHL)…”
Get full text
Journal Article -
18
Results According to Age in Avex, a Randomized Phase 3 Trial of Bevacizumab with Capecitabine for Elderly Patients with Mcrc
Published in Annals of oncology (01-06-2013)Get full text
Journal Article -
19
Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer
Published in Journal of clinical oncology (20-05-2013)“…Abstract only 3521 Background: Elderly patients (pts) are underrepresented in clinical trials. The open-label phase III trial AVEX evaluated the benefit of…”
Get full text
Journal Article -
20
Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
Published in Journal of clinical oncology (01-02-2013)“…Abstract only 337 Background: Elderly patients (pts) comprise the majority of pts diagnosed with mCRC, although they are in general underrepresented in…”
Get full text
Journal Article